Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Veenstra

Showing results (61-70 of 284) with videos related to

Pageof 29
Sort By:
Proteins|September 3, 1998
Can one predict protein stability? An attempt to do so for residue 133 of T4 lysozyme using a combination of free energy derivatives, PROFEC, and free energy perturbation methodsL Wang, D L Veenstra, R J Radmer, et al.
Gastrointestinal Endoscopy|January 9, 2003
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindredsStephen J Rulyak, Michael B Kimmey, David L Veenstra, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 26, 2005
Economic analyses of human genetics services: a systematic reviewJosh J Carlson, Nora Beidler Henrikson, David L Veenstra, et al.
Journal of Medical Economics|December 24, 2016
The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplantDavid L Veenstra, Gregory F Guzauskas, Kathleen F Villa, et al.
Journal of Alzheimer'S Disease : JAD|February 8, 2011
CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohortLisa M Bloudek, D Eldon Spackman, David L Veenstra, et al.
Journal of Clinical Gastroenterology|December 17, 2004
Cost of chronic hepatitis B infection in the United StatesTodd A Lee, David L Veenstra, Uchenna H Iloeje, et al.
Clinical Pharmacology and Therapeutics|March 29, 2012
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary interventionG F Guzauskas, D A Hughes, S M Bradley, et al.
American Journal of Public Health|August 31, 2001
Modeling the cost and outcomes of pharmacist-prescribed emergency contraceptionK D Marciante, J S Gardner, D L Veenstra, et al.
Journal of Managed Care & Specialty Pharmacy|November 30, 2020
The use of real-world evidence in ICER's scoping process and clinical evidence assessmentsBoshen Jiao, David L Veenstra, Woojung Lee, et al.
Journal of Medical Economics|April 11, 2014
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysisPreeti S Bajaj, David L Veenstra, Hans-Peter Goertz, et al.
Pageof 29

Showing results (61-70 of 284) with videos related to

Sort By:
Pageof 29
Proteins|September 3, 1998
Can one predict protein stability? An attempt to do so for residue 133 of T4 lysozyme using a combination of free energy derivatives, PROFEC, and free energy perturbation methodsL Wang, D L Veenstra, R J Radmer, et al.
Gastrointestinal Endoscopy|January 9, 2003
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindredsStephen J Rulyak, Michael B Kimmey, David L Veenstra, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 26, 2005
Economic analyses of human genetics services: a systematic reviewJosh J Carlson, Nora Beidler Henrikson, David L Veenstra, et al.
Journal of Medical Economics|December 24, 2016
The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplantDavid L Veenstra, Gregory F Guzauskas, Kathleen F Villa, et al.
Journal of Alzheimer'S Disease : JAD|February 8, 2011
CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohortLisa M Bloudek, D Eldon Spackman, David L Veenstra, et al.
Journal of Clinical Gastroenterology|December 17, 2004
Cost of chronic hepatitis B infection in the United StatesTodd A Lee, David L Veenstra, Uchenna H Iloeje, et al.
Clinical Pharmacology and Therapeutics|March 29, 2012
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary interventionG F Guzauskas, D A Hughes, S M Bradley, et al.
American Journal of Public Health|August 31, 2001
Modeling the cost and outcomes of pharmacist-prescribed emergency contraceptionK D Marciante, J S Gardner, D L Veenstra, et al.
Journal of Managed Care & Specialty Pharmacy|November 30, 2020
The use of real-world evidence in ICER's scoping process and clinical evidence assessmentsBoshen Jiao, David L Veenstra, Woojung Lee, et al.
Journal of Medical Economics|April 11, 2014
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysisPreeti S Bajaj, David L Veenstra, Hans-Peter Goertz, et al.
Pageof 29